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system the combined screening/risk-based strategy and
the risk-based strategy are efﬁcient strategies with rea-
sonable cost-effectiveness.
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OBJECTIVES: To evaluate two screening programs for
Chlamydia Trachomatis (CT) in France by measuring cost
per case and cost per treated case. METHODS: We eval-
uated the cost-effectiveness ratios of two CT screening
strategies using a decision tree model. Strategy A involved
screening of asymptomatic women only with partner
notiﬁcation; Strategy B involved screening of both asymp-
tomatic men and women with partner notiﬁcation. The
current strategy of no screening was not evaluated. Clin-
ical pathways were validated by a panel of experts. Direct
cost analysis was performed from the point of view of the
French National Health Insurance System. RESULTS:
Overall, 347 women, and their partners could be treated
by strategy A, and 296 individuals and their partners by
strategy B. The total cost of strategy B was lower than
that of strategy A (€213,400 compared to €250,558).
Costs per case and costs per treated case were compara-
ble for the two strategies, €557 and €722 respectively.
According to a sensitivity analysis, the key variables were:
CT prevalence, male participation rate, and likelihood
that a man should consult a doctor. CONCLUSIONS:
This is the ﬁrst model for CT screening built on French
data and thus a useful tool for French health policy deci-
sion-makers as it provides estimates for budgetary impact
analysis. Its limitations are the hypotheses on which it is
based (averted outcomes, direct costs . . .). Besides com-
paring the cost-effectiveness of screening, our study high-
lighted the need to standardize clinical practice and
develop a good communication program.
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OBJECTIVES: To estimate the incremental cost-
effectiveness ratio (ICER) of routine meningococcal
serogroup C conjugate vaccination of children at 2, 3,
and 4, or at 5 and 6 months instead of at 14 months in
the Netherlands and to determine the impact of includ-
ing herd-immunity. METHODS: The analysis was per-
formed from a societal perspective and in accordance to
the Dutch guidelines for pharmacoeconomic research,
using a cohort model. Direct and indirect (friction cost
method) costs were considered. Future costs and effects
were discounted at 4% and 2000 was chosen as baseline
year. A vaccine effectiveness of 90% (based on UK data)
and a vaccine protection duration of 20 years (based on
the experience with Haemophilus inﬂuenzae type b) were
used. Also on the basis of UK data, we assumed that 70%
of all unvaccinated persons aged 0–14 months are pro-
tected because of the herd-immunity effect caused by 
the recent meningococcal C conjugate vaccination of all
persons aged 14 months to 18 years. RESULTS: For
immunization of children at 2, 3, and 4 (5 + 6) months,
the herd-immunity effect decreases the yearly number of
additional life years gained from 51 (36) to 15 (11) but
leads to a strong increase of the ICER from €149,000
(€105,000) per life year gained to €497,000 (€349,000)
per life year gained. Even if only a herd-immunity effect
of 50% is assumed, the ICER still increases to about
€298,000 (€209,000) per life year gained. These results
are sensitive to the protection duration and effectiveness
of the vaccine and the meningococcal C incidence. CON-
CLUSIONS: The inclusion of herd-immunity decreases
the rendered small health gain and thus leads to even less
favorable cost-effectiveness ratios for vaccination of chil-
dren aged less than one year. Hence, the current Dutch
vaccination strategy of routine vaccinating children at 14
months should not be changed.
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Respiratory syncytial virus (RSV) is a leading cause of a
lower respiratory tract infection in infants and is respon-
sible for increased hospitalization, morbidity, and deaths
amongst high-risk individuals including those who are
born prematurely. As the treatment of RSV infections is
limited the analysis was focused on prophylactic therapy
with palivizumab, a humanized murine monoclonal anti-
body that provides passive immunity against RSV.
OBJECTIVES: To evaluate costs and cost-effectiveness of
RSV prophylaxis among infants born at less than 32
weeks gestation in Poland. METHODS: Decision tree
analysis was used to compare cost-effectiveness of two
strategies, palivizumab and no prophylaxis, among a
hypothetical cohort of infants born <32 gestational age.
Probabilities were derived from published trials. Costs
encompassed: drug costs, costs of non-intensive and
intensive pediatric hospital care and costs of asthma treat-
ment up to age 7. The discount rate of costs was set at
